Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Amiodarone Hydrochloride
Amiodarone hydrochloride is a substance used to help control serious abnormal heart rhythms.
Dronedarone Hydrochloride
Dronedarone hydrochloride is a substance that helps maintain a regular heart rhythm in people with atrial fibrillation or atrial flutter.
Flecainide Acetate
Flecainide acetate is a substance that helps restore normal heart rhythm by stabilizing electrical activity to treat certain irregular heartbeats.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Evangelisches Klinikum Bethel gGmbH
Clinic for Neurology
Bielefeld, Germany
Universitaetsklinikum Bonn AöR
Clinic for Vascular Neurology
Bonn, Germany
Technische Universitaet Dresden
Clinic for Neurology
Dresden, Germany

Sponsor: University Medical Center Hamburg-Eppendorf
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.